Viking Therapeutics. has filed a patent for FXR agonists, which are compounds that can be used to prevent, treat, or improve fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. These compounds can be used alone or in combination with thyroid receptor agonists. GlobalData’s report on Viking Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Viking Therapeutics, Peptide pharmacophores was a key innovation area identified from patents. Viking Therapeutics's grant share as of September 2023 was 10%. Grant share is based on the ratio of number of grants to total number of patents.
Fxr agonists for treating fatty liver diseases
A recently filed patent (Publication Number: US20230226038A1) describes a compound of Formula (I) and its various derivatives. The compound can have different substituents, such as phenyl or pyridyl, which can be further substituted with other groups. One specific derivative mentioned is (trifluoromethoxy)phenyl. The compound can also have different groups attached to R2, such as phenyl, pyridyl, or C3-6 cycloalkyl. The compound can also have different groups attached to G, such as phenyl, pyridine, imidazole, pyrrole, and others. These groups can be further substituted with other groups. The patent also describes compounds of Formula (IIa) and (IIaa), which are specific derivatives of the compound of Formula (I).
The patent also discloses the use of these compounds in pharmaceutical compositions for the prevention, treatment, or amelioration of fatty liver diseases, including steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. The compounds can also be used for the prevention, treatment, or amelioration of fibrosis, fibrotic conditions, or fibrotic symptoms. The compounds can reduce the amount of extracellular matrix proteins and collagen in tissues. Additionally, the patent describes the use of these compounds in the prevention, treatment, or amelioration of various diseases and disorders, including liver fibrosis, renal fibrosis, biliary fibrosis, pancreatic fibrosis, chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis, primary biliary cirrhosis, and idiopathic fibrosis.
Furthermore, the patent discloses a method of administering a compound of Formula (I) in combination with a TR-ß agonist for the prevention, treatment, or amelioration of fatty liver diseases and fibrosis-related conditions. The TR-ß agonist can be a compound of Formula (I) or a compound with a similar structure. The method can result in the reduction of
To know more about GlobalData’s detailed insights on Viking Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
